Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer

Table 1 Correlation of serum POSTN levels and clinicopathological characteristics of BCa patients

Characteristics	Number	POSTN(ng/mL) Median (interquartile range)	P value
Age (median)	53.0
≤ 60	168	23.49 (15.64–35.50)
> 60	63	19.09 (13.12–31.59)	0.32^a
Tumor size (maximum diameter)*
≤ 2	46	14.93 (10.07–19.02)
> 2& ≤ 5	69	17.99 (12.48–27.95)
> 5	22	28.05 (19.56–42.79)	< 0.0001^b
TNM stage
I	31	16.11 (11.83–22.46)
II	72	17.59 (10.14–25.38)
III	34	21.01 (16.13–32.65)
IV	94	26.77 (17.85–49.95)	< 0.0001^b
Lymph node metastasis
No	78	16.47 (11.06–24.31)
Yes	153	24.72 (16.29–39.68)	< 0.0001^a
Distant metastasis
No	137	17.55 (12.26–26.45)
Yes	94	26.77 (17.85–49.95)	< 0.0001^a
Molecular subtype
Luminal A	77	21.09 (12.76–31.85)
Luminal B	81	19.67 (13.58–28.91)
HER2-enriched	38	25.85 (13.72–50.08)
Triple negative	35	18.24 (15.20–26.79)	0.59^b
Chemotherapy efficacy monitoring
Non-HER2-targeted	28	22.01 (15.46–30.85)
HER2-targeted	30	24.05 (16.93–51.02)	0.43^a
Response
PR	33	24.61 (16.88–45.47)
Non-PR	25	20.54 (15.67–27.02)	0.44^a

ISSN: 1475-2867